← Back to Screener
Anavex Life Sciences (AVXL)
Price$2.57
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-40.82%
Price vs S&P 500 (4W)-20.18%
VGM Score15.08
Market Capitalization$238.17M
All Metrics
Book Value / Share (Quarterly)$1.37
P/TBV (Annual)4.07x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.37
Price vs S&P 500 (YTD)-35.97%
EPS (TTM)$-0.46
10-Day Avg Trading Volume1.29M
EPS Excl Extra (TTM)$-0.46
EPS (Annual)$-0.54
ROI (Annual)-48.89%
Cash / Share (Quarterly)$1.42
ROA (Last FY)-44.67%
EBITD / Share (TTM)$-0.52
ROE (5Y Avg)-35.39%
Cash Flow / Share (Annual)$-0.45
P/B Ratio1.88x
P/B Ratio (Quarterly)2.51x
Net Income / Employee (Annual)$-1,364,000
Net Interest Coverage (TTM)-155.83x
ROA (TTM)-35.01%
EPS Incl Extra (Annual)$-0.54
Current Ratio (Annual)11.60x
Quick Ratio (Quarterly)20.81x
3-Month Avg Trading Volume1.34M
52-Week Price Return-66.97%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.80
52-Week High$13.99
EPS Excl Extra (Annual)$-0.54
Tangible BV CAGR (5Y)42.50%
26-Week Price Return-32.90%
Quick Ratio (Annual)11.56x
13-Week Price Return-46.01%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)20.87x
Enterprise Value$106.42M
Book Value / Share Growth (5Y)20.07%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.18
3-Month Return Std Dev93.50%
Net Income / Employee (TTM)$-1,174,900
ROE (Last FY)-48.89%
Net Interest Coverage (Annual)-29.59x
EPS Basic Excl Extra (Annual)$-0.54
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.46
ROI (TTM)-38.76%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.83
Price vs S&P 500 (52W)-91.33%
Year-to-Date Return-27.81%
5-Day Price Return-13.76%
EPS Normalized (Annual)$-0.54
ROA (5Y Avg)-32.41%
Month-to-Date Return-15.18%
EBITD / Share (Annual)$-0.60
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-35.39%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.46
P/TBV (Quarterly)3.95x
P/B Ratio (Annual)8.06x
Book Value / Share (Annual)$1.09
Price vs S&P 500 (13W)-54.26%
Beta1.17x
Revenue / Share (TTM)$0.00
ROE (TTM)-38.76%
52-Week Low$2.56
mGradeF
vgmGradeF
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.00
4.00
4.00
4.13
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AVXLAnavex Life Sciences | — | — | F | $2.57 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Anavex Life Sciences is a clinical-stage biopharmaceutical company developing precision medicine treatments for central nervous system disorders with high unmet need. The company uses genomic biomarker analysis to advance programs targeting Alzheimer's disease, Parkinson's disease, schizophrenia, and rare neurological conditions including Rett syndrome. Its lead candidates, ANAVEX 2-73 and ANAVEX 3-71, are in clinical development, with additional compounds in earlier-stage programs.